AXSM — Axsome Therapeutics, Inc.

Axsome Therapeutics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $191.2 million, a 57% increase year-over-year.
• AUVELITY Revenue: $153.2 million (up 59% YoY).
• SUNOSI Revenue: $33.9 million (up 34% YoY).
• SYMBRAVO Revenue: $4.1 million.
• Net Loss: $64.5 million ($1.26 per share), compared to a net loss of $59.4 million ($1.22 per share) in Q1 2025.
• Cash Position: Ended Q1 with $305 million in cash and equivalents, down from $323 million at the end of 2025.

2. Strategic Updates and Business Highlights:

• FDA Approval: AUVELITY received FDA approval for treating agitation associated with Alzheimer's disease, marking a significant milestone.
• Sales Force Expansion: Increased sales force for AUVELITY to approximately 630 representatives, enhancing market reach.
• Pipeline Development: Six product candidates in the pipeline, including AXS-12 for narcolepsy and AXS-20 for schizophrenia and Tourette syndrome.
• Market Access Improvements: AUVELITY's commercial coverage reached 86% of lives, with significant progress in payer coverage for SYMBRAVO and SUNOSI.

3. Forward Guidance and Outlook:

• Peak Sales Estimates: AUVELITY projected to achieve at least $8 billion in annual revenue at peak, with equal contributions from MDD and Alzheimer's agitation indications.
• Revenue Growth Expectation: Continued revenue growth anticipated throughout 2026, driven by AUVELITY and overall commercial portfolio execution.
• Clinical Trials: Plans to initiate multiple Phase III trials for various products in the pipeline within the next few months.

4. Challenges and Points of Concern:

• High SG&A Expenses: SG&A expenses rose significantly to $185 million, primarily due to prelaunch activities for AUVELITY and sales force expansion.
• Net Losses: Continued net losses raise concerns about profitability timelines, although management emphasizes a focus on revenue growth first.
• Competitive Landscape: Potential competition from emerging treatments, including Orexin-2 receptor agonists for narcolepsy, poses risks to market share.

5. Notable Q&A Insights:

• Long-Term Care (LTC) Market: Management acknowledges the importance of LTC in the AUVELITY market strategy, with plans to engage prescribers in both community and LTC settings.
• Market Dynamics: The approval of AUVELITY for Alzheimer's agitation may lead to significant patient uptake, but exact projections remain uncertain.
• Sales Force Strategy: Sales representatives will initially focus on specific products, but there is potential for cross-promotion as the portfolio expands.
• Payer Engagement: Early discussions with payers for AXS-12 indicate interest in new narcolepsy treatments, but pricing discussions are not yet finalized.
• IRA Implications: Any potential impact from the Inflation Reduction Act (IRA) on AUVELITY is not expected until 2031, and current projections account for this.

Overall, Axsome Therapeutics demonstrated strong financial growth and strategic advancements in Q1 2026, with significant potential for future revenue growth driven by AUVELITY and an expanding pipeline, despite facing challenges related to high expenses and competitive pressures.